Trial reportCancer prevention research (Philadelphia, Pa.)2016
A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.
Trial report in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.Cancer prevention research (Philadelphia, Pa.) · 2019Trial
- Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- The Therapeutic Potential of Myo-Inositol in Managing Patients with Respiratory Diseases.International journal of molecular sciences · 2025Review
- Review
- Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer.Translational lung cancer research · 2023Article
- Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis.Respiratory research · 2023Article
- The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.International journal of molecular sciences · 2023Review
- Phytate Intake, Health and Disease: "Let Thy Food Be Thy Medicine and Medicine Be Thy Food".Antioxidants (Basel, Switzerland) · 2023Review
- Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.Frontiers in oncology · 2023Article
- Article
- Cancer Prevention by Natural Products Introduced into the Diet-Selected Cyclitols.International journal of molecular sciences · 2020Review
- Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia?Medical hypotheses · 2020Article
- Recent Advances and the Potential for Clinical Use of Autofluorescence Detection of Extra-Ophthalmic Tissues.Molecules (Basel, Switzerland) · 2020Review
- Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.Nature communications · 2019Article
- Dietary myo-inositol chemoprevents lung carcinogenesis via boosting immune system in Kras mouse model.Journal of thoracic disease · 2019Article
- Alcohol consumption analysis among patients with liver disease in China.Chinese medical journal · 2019Article
- AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer.American journal of respiratory and critical care medicine · 2018Article
- AJournal of thoracic disease · 2018Article
- Breast Cancer Prevention: Current Approaches and Future Directions.European journal of breast health · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 2 institutions in 2 countries.
Funding
Abstract
Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906-14. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.